Regulus Therapeutics Inc. (NASDAQ:RGLS) Weekly Ratings as of Jun 27, 2018

June 27, 2018 - By Carey Conley

Regulus Therapeutics Inc. (NASDAQ:RGLS) Corporate Logo
During Q1 2018 the big money sentiment decreased to 1.11. That’s change of 0.05, from 2017Q4’s 1.16. 8 investors sold all, 10 reduced holdings as Regulus Therapeutics Inc. ratio dropped. 11 increased positions while 9 funds took positions. Funds hold 50.71 million shares thus 4.62% less from 2017Q4’s 53.17 million shares.
22,475 are owned by Hightower Advsr Lc. Bvf Il accumulated 13.97 million shs. 33,260 were accumulated by Utd Service Automobile Association. Ascend Cap Ltd Limited Liability Company holds 0.03% of its capital in Regulus Therapeutics Inc. (NASDAQ:RGLS) for 1.00M shs. Dowling Yahnke Ltd Liability Corp invested in 12,000 shs or 0% of the stock. Northern, Illinois-based fund reported 187,492 shs. 737,995 were reported by Point72 Asset Mngmt Ltd Partnership. Moreover, California Employees Retirement System has 0% invested in Regulus Therapeutics Inc. (NASDAQ:RGLS). Blackrock Inc holds 0% or 780,792 shs. The Ohio-based Meeder Asset Mngmt Inc has invested 0% in Regulus Therapeutics Inc. (NASDAQ:RGLS). Nea Com Limited Company has 0.35% invested in Regulus Therapeutics Inc. (NASDAQ:RGLS). Morgan Stanley invested 0% of its capital in Regulus Therapeutics Inc. (NASDAQ:RGLS). Fmr Ltd Liability has invested 0% in Regulus Therapeutics Inc. (NASDAQ:RGLS). Millennium Limited Co has 0% invested in Regulus Therapeutics Inc. (NASDAQ:RGLS). Savings Bank Of Mellon owns 67,448 shs for 0% of their capital.

Regulus Therapeutics Inc. (NASDAQ:RGLS) Ratings Coverage

Total analysts of 5 have positions in Regulus Therapeutics (NASDAQ:RGLS) as follows: 2 rated it a “Buy”, 0 with “Sell” and 3 with “Hold”. The positive are 40%. Since January 5, 2018 according to StockzIntelligence Inc Regulus Therapeutics has 7 analyst reports. On Tuesday, March 27 the firm has “Hold” rating by FBR Capital given. On Thursday, May 17 Wedbush maintained Regulus Therapeutics Inc. (NASDAQ:RGLS) rating. Wedbush has “Buy” rating and $300 target. On Thursday, February 8 the firm has “Buy” rating given by Wedbush. On Thursday, March 8 the firm has “Market Perform” rating given by BMO Capital Markets. On Monday, March 12 the stock has “Buy” rating by Wedbush. Listed here are Regulus Therapeutics Inc. (NASDAQ:RGLS) PTs and latest ratings.

17/05/2018 Broker: Wedbush Rating: Buy New Target: $3.0000 Maintain
28/03/2018 Broker: B. Riley & Co Rating: Neutral New Target: $1 Initiates Coverage On
27/03/2018 Broker: FBR Capital Rating: Hold New Target: $1.0000 Initiate
12/03/2018 Broker: Wedbush Rating: Buy New Target: $3.0 Maintain
08/03/2018 Broker: BMO Capital Markets Old Rating: Market Perform New Rating: Market Perform Old Target: $1 New Target: $1.37 Maintain
08/02/2018 Broker: Wedbush Rating: Buy New Target: $4.0 Maintain
05/01/2018 Broker: Leerink Swann Rating: Outperform New Target: $2 Initiates Coverage On

Ticker’s shares touched $0.66 during the last trading session after 0.60% change.It’s downtrending since June 27, 2017 and is 45.33% down. RGLS underperformed by 57.90% the S&P 500.

Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States.The company has $68.85 million market cap. The firm uses its microRNA product platform to develop anti-miRs, which are chemically modified and single-stranded oligonucleotides.Currently it has negative earnings. The Company’s clinical development products include RG-101, a GalNAc-conjugated anti-miR targeting miR-122 to treat patients with hepatitis C virus infection; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome; RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107 for the treatment of non-alcoholic fatty liver disease; RGLS5040, an anti-miR targeting microRNA-27 for the treatment of cholestatic disease; and RGLS4326, an anti-miR targeting microRNA-17 for the treatment of autosomal dominant polycystic kidney disease.

There’s a substantial Regulus Therapeutics Inc. (NASDAQ:RGLS) news brought out by Nasdaq.com. It’s a report titled: “New Research: Key Drivers of Growth for CNA Financial, AutoNation, Hess, Infinity Pharmaceuticals, Regulus …” on June 12, 2018.

Regulus Therapeutics Inc. (NASDAQ:RGLS) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.